As such, the Her2 model has been utilized extensively in the design and testing of Her2 therapeutics, including those designed to target Her2+ breast cancer stem cells [48], Her2 DNA vaccines (in the presence or absence of CD25hi regulatory T cells) [49–51] as well as in adoptive immunotherapy using genetically modified T cells [22,23]. This evidence concerns the gene ERBB2 and breast cancer.